Ouro Fino Sa?de Animal Participa?es S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 11, 2021 at 04:16 pm EST
Share
Ouro Fino Sa?de Animal Participa?es S.A. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was BRL 234.84 million compared to BRL 225.19 million a year ago. Net income was BRL 34.77 million compared to BRL 45.5 million a year ago. Basic earnings per share from continuing operations was BRL 0.64456 compared to BRL 0.84341 a year ago. Diluted earnings per share from continuing operations was BRL 0.64456 compared to BRL 0.84341 a year ago.
For the nine months, sales was BRL 634.61 million compared to BRL 509.61 million a year ago. Net income was BRL 76.24 million compared to BRL 58.08 million a year ago. Basic earnings per share from continuing operations was BRL 1.41331 compared to BRL 1.07657 a year ago. Diluted earnings per share from continuing operations was BRL 1.41331 compared to BRL 1.07657 a year ago.
Ouro Fino Saude Animal Participacoes S.A., also known as Ourofino, is a Brazil-based company engaged in the animal health market business sector in Latin America. The Company manufactures veterinary products using scientific technology in the Company's laboratories. The Company's products are divided into six sectors: Wholesale, Birds, Cattle, Equine, Pet and Pigs. The Wholesale area is divided into four lines: Anti-Mastiticos, producing antibiotics killing bacteria and lumps; Antimicrobial, which focuses on the treatment of bacterial infectious diseases; Ectoparasiticides, concentrated on insect repellent products, and Endectocides, which is the treatment and control of internal and external diseases of cattle, sheep and swine parasites. There is also one additional line of products divided for additives, biological, inoculants, diagnostic kit, probiotics, silage and other supplements, among others.
OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES S.A. 
